Qrons Announces Launch of its New Website Reflecting Expanded Neuronal Diseases Goals

Rhea-AI Summary

Qrons Inc. (OTCQB:QRON) has launched a newly redesigned website aimed at enhancing public education on its expanded focus in treating neuronal diseases beyond traumatic brain injury (TBI). The website reflects Qrons' synergy of tissue engineering, stem cells, and machine learning technologies. CEO Jonah Meer expressed enthusiasm over leveraging proprietary knowledge and collaboration with Israeli biotech ventures. The new site will enable more flexible updates for future developments and reflects the company's commitment to innovative biotechnology solutions.

Positive

• Launch of a redesigned website to enhance public education on neuronal disease treatments.
• Increased focus on broader applications of TBI research.
• Collaboration opportunities with Israeli biotech startups.

Negative

• None.

NEW YORK, NY / ACCESSWIRE / February 11, 2021 / Qrons Inc. (OTCQB:QRON), an innovative biotechnology company developing next generation treatments for unmet neuronal diseases, using tissue engineering, stem cells and machine learning synergic technologies is proud to announce the launch of its newly redesigned web site at https://www.qrons.com

The new site reflects Qrons' focus on extending its proprietary traumatic brain injury ("TBI") research to create a platform making use of synergic technologies to combat a broader range of neuronal diseases.

Jonah Meer, Qrons' Chief Executive Officer, commented, " We are thrilled to introduce our new website to educate the public about our expanded goal of leveraging our progress and proprietary knowledge to date with Israeli biotechnologies in a broader quest to treat neuronal diseases."

Ido Merfeld, Qrons' co-founder and President said, "We believe that our research discoveries may have the potential for broader applications beyond the treatment of TBIs if we are able to develop alongside new next generation technologies."

Liat Hammer, PhD, Qrons' Director of Research added "We hope to be able to collaborate with Israeli biotech startups whose technologies we believe can aid in the treatment of TBIs and other neuronal diseases."

The new website design will also provide Qrons greater flexibility in updating its website going forward.

About Qrons Inc.

Headquartered in New York City, with research conducted in Israel, Qrons is an innovative biotechnology company dedicated to developing biotech products, treatments and technologies that create a platform to combat neuronal diseases. Qrons' approach is to seek to marshal and leverage the remarkable advances made in the fields of artificial intelligence (AI), machine learning (ML), molecular biology, stem cells and tissue engineering for deployment in the fight against neuronal diseases,. through development, acquisitions and investments. Please visit https://www.qrons.com

Forward Looking Statement

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, develop products, create alliances and attract and retain qualified professionals, technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.

Contact:

Qrons Inc.
Jonah Meer
Chief Executive Officer
212-945-2080

SOURCE: Qrons Inc.

View source version on accesswire.com:
https://www.accesswire.com/629341/Qrons-Announces-Launch-of-its-New-Website-Reflecting-Expanded-Neuronal-Diseases-Goals

FAQ

What is the significance of Qrons Inc.'s new website launch?

The new website aims to educate the public on Qrons' expanded focus on treating neuronal diseases beyond traumatic brain injury.

What technologies does Qrons Inc. utilize in its research?

Qrons uses a combination of tissue engineering, stem cells, and machine learning technologies to develop treatments.

Who are the key executives commenting on the new website for Qrons?

CEO Jonah Meer and co-founder Ido Merfeld provided insights on the new website's goals and opportunities.

What are Qrons Inc.'s future research collaborations focused on?

The company aims to collaborate with Israeli biotech startups to enhance treatments for TBI and other neuronal diseases.

What is Qrons Inc.'s stock symbol?

Qrons Inc. is traded under the stock symbol QRON on the OTCQB.